Fulgent Genetics, Inc. (FLGT) Tops Q1 EPS by 73c; Raises Outlook

Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q1 EPS of $6.59, $0.73 better than the analyst estimate of $5.86. Revenue for the quarter came in at $359.4 million versus the consensus estimate of $321.51 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2021 EPS of $12.50, versus the consensus of $12.27. Fulgent Genetics, Inc. sees FY2021 revenue of $830-800 million, versus the consensus of $789.4 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.

You May Also Be Interested In

• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
• LG Energy 2q Oper Profit 113.3b Won, Est. 210.66b Won - Bloomberg
• Eli Lilly (LLY) PT Raised to $1,370 at Truist Securities